- €797.12m
- €743.62m
- €19.52m
Europe Research Roundup: Dassault Systemes, Husqvarna, Swedbank
Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
Brief: Medincell Appoints Philippe Guy As Chairman Of Supervisory Board
Brief: Medincell Posts H1 Income From Ordinary Activities Of EUR 8.2 Million
Brief: Medincell Announces Departure Of CFO Jaime Arango
Brief: Medincell: Completion Of Patient Enrollment In Phase 3 Study Of F14
Brief: Medincell Has Received Last Tranche Of EUR 10 Million From European Investment Bank Loan
Brief: Medincell FY Net Loss Widens To EUR 29.5 Million
Brief: Medincell: Phase 1 Data Of Mdc-Tjk For Schizophrenia Patients
Brief: MedinCell Launches Global Offering For About EUR 25 Mln
Brief: Medincell: FDA Approval Of mdc-IRM
Brief: Teva & Medincell Announce FDA Approval Of Uzedy (Risperidone) Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults
Brief: Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic
Brief: MedinCell H1 Net Financial Loss At 2.1 Million Euros
Brief: Medincell: Additional $4 Mln Received For 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
Brief: EIB And Medincell Sign New €40 Million Loan Agreement
Brief: Medincell's Partner Teva Today Announced Refiling For Approval Of Mdc-Irm And Confirmed Planned Launch In U.S. In H1 2023
Brief: MedinCell Signs Licence Deal With Medicines Patent Pool For Malaria
Brief: Medincell Secures Additional EUR 20 Mln Financing With European Investment Bank